Altering the effects of testosterone on prostate cancer cells by blocking androgen production or action is a critical part of treating this malignancy. The appropriate timing of androgen blockade for advanced prostate cancer is controversial. Despite many phase-III studies, gaps in clinical information still remain, and some questions are still not conclusively answered. This review concentrates on high-level evidence to address common clinical situations in advanced and metastatic prostate cancer. Additionally, the side-effects of androgen blockade have become increasingly visible and relevant.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.beem.2008.01.013 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!